The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection

Current Urology Reports

Volumn 4, Issue 3, 2003, Pages 248-252

  Chaussy, Christian ^a   Thüroff, Stefan ^a  

^a Krankenhaus Harlaching   (Germany)

Author keywords

Catheter Time; HIFU Treatment; High Intensity Focus Ultrasound; Localize Prostate Cancer; Suprapubic Catheter

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEASIBILITY STUDY; FOLLOW UP; HUMAN; MALE; MICTURITION DISORDER; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PATHOLOGY; POSTOPERATIVE COMPLICATION; PROSTATE TUMOR; QUALITY OF LIFE; TIME; TRANSURETHRAL RESECTION; ULTRASOUND THERAPY;

AGED; COMBINED MODALITY THERAPY; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POSTOPERATIVE COMPLICATIONS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TIME FACTORS; TRANSURETHRAL RESECTION OF PROSTATE; ULTRASONIC THERAPY; URINATION DISORDERS;

EID: 0042410979     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-003-0077-0     Document Type: Article

References (11)

1. Chapelon JY, Margonari J, Vernier F, et al.: In vivo effects of high intensity ultrasound on prostatic adenocarcinoma dunning R3327. Cancer Res 1992, 52:6353–6357.
2. Chapelon JY, Margonari J, Theillère Y, et al.: Effects of highenergy focused ultrasound on kidney tissue in the rat and the dog. Eur Urol 1992, 22:147–152.
3. Dosterhof GO, Cornel EB, Smits GAHJ, et al.: Influence of high intensity focused ultrasound on the development of metastases. Eur Urol 1997, 32:91–95.
4. Gelet A, Chapelon JY, Margonari J, et al.: Prostatic tissue destruction by high intensity focused ultrasound: experimentation on canine prostate. J Endourol 1993, 7:249–253.
5. Gelet A, Chapelon JY, Bouvier R, et al.: Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience. Eur Urol 1996, 29:174–183.
6. Gelet A, Chapelon JY, Bouvier R, et al.: Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: preliminary results. J Urol 1999, 161:156–162. Albert Gelet, who began the clinical studies for HIFU in patients with localized prostatic cancer, reports about his experiences. DOI: 10.1016/S0022-5347(01)62087-1
7. Chaussy C, Thüroff S: Results and side effects of high intensity focused ultrasound in localized prostate cancer. J Endourol 2001, 15:437–440. DOI: 10.1089/089277901300189501
8. Thüroff S, Chaussy C: High intensity focused ultrasound: complications and adverse events. Mol Urol 2000, 4:183–187. The paper shows the development of HIFU treatment. It describes how technical development and treatment strategy during 3 years would increase efficacy and decrease postapplicative morbidity. The results showed that HIFU could be established as a clinical routine treatment for selected patients with localized prostatic cancer.
9. Gelet A, Chapelon JY, Bouvier R, et al.: Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome. Eur Urol 2001, 40:124–129. DOI: 10.1159/000049761
10. Chaussy C, Thüroff S: High intensity focused ultrasound in prostate cancer: results after 3 years. Mol Urol 2000, 4:179–182. The paper shows the development of HIFU treatment. It describes how technical development and treatment strategy during 3 years would increase efficacy and decrease post-applicative morbidity. The results were that HIFU could be established as a clinical routine treatment for selected patients with localized prostatic cancer.
11. Gelet A, Chapelon JY, Bouvier R, et al.: Transrectal high intensity focused ultrasound: minimally invasive therapy of localized prostate cancer. J Endourol 2000, 14:519–528. DOI: 10.1089/end.2000.14.519